A Phase 1 interventional study of Microarray patch A and Microarray patch B in Psoriasis Vulgaris, sponsored by LEO Pharma. Completed at 2 sites in Germany. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-02-24.
Sponsored by LEO Pharma · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies testing calcipotriene in Psoriasis — 2 open to participants now, 2 under way, none of them phase 3. calcipotriene · Psoriasis.
Among the 47 studies testing calcipotriene in Psoriasis, this one is the 41st largest by enrollment, is one of 2 that started in 2019, is one of 5 in phase 1, and was the 38th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →2 of the 47 studies testing calcipotriene in Psoriasis are open now, in 2 countries. Recruiting first, the newest first:
Xijing Hospital · Sites in China
Ages 18–65
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
calcipotriene: first FDA approval 1993 (DOVONEX). What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 12 · Phase 3 19 · Phase 4 12
First in 2004; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 15 is below the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 200 across the 47 interventional studies. Of the 41 that completed or were terminated, 21 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 47 have an industry lead sponsor. The 10 most frequent:
LEO Pharma is the lead sponsor of 225 studies on the registry; 5 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 24 (75%) have results posted.
79 studies in Psoriasis by LEO Pharma: 1 open now, 2 under way, none of them phase 3. Of 77 finished, 36 (47%) have results posted.
Among the 79 studies in Psoriasis by LEO Pharma, this one is the 66th largest by enrollment of the 71 interventional ones that give a count, is one of 3 that started in 2019, is one of 19 in phase 1, and was the 73rd registered.
LEO Pharma’s Psoriasis studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 47 studies testing calcipotriene in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among LEO Pharma’s 79 in Psoriasis:
This tab as a report to print or save as PDF → With an account.
To assess safety, tolerability and pharmacodynamics effect of treatment with microarray patches containing calcipotriol and betamethasone dipropionate.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
21 day treatment, once weekly, 3 applications in total, transdermal patch for cutaneous use
Drug: Microarray patch A
21 day treatment, 3 times weekly, 9 applications in total, transdermal patch for cutaneous use
Drug: Microarray patch B
21 day treatment, once weekly, 3 applications in total, transdermal patch for cutaneous use, no active substance
Drug: Placebo
21 day treatment, paused on day 7, day 14 and day 21, Cutaneous use
Drug: Daivobet
Microarray patch
Also known as: Calcipotriol, Betamethasone dipropionate
Microarray patch
Also known as: Calcipotriol, Betamethasone dipropionate
Microarray patch vehicle
Daivobet Gel
Also known as: Calcipotriol, Betamethasone dipropionate
Overall number of treatment-emergent adverse events.
Time frame: First IMP application up to trial end (Day 50)
Number of treatment-emergent application site reactions, by treatment
Time frame: First IMP application up to trial end (Day 50)
Change from baseline to Day 22 (EoT) in haematology parameters.
RBC, WBC, haemoglobin, haematocrit, platelets, white cell differentials; measured in SI units.
Time frame: From baseline up to EoT (Day 22)
Change from baseline to Day 22 (EoT) in clinical chemistry parameters.
Sodium, potassium, BUN, glucose, AST, ALT, gamma GT, AP, calcium, phosphate, albumin, total cholesterol, LDH, total protein, creatinine, total bilirubin; measured in SI units.
Time frame: From baseline to EoT (Day 22)
Change from baseline to Day 22 (EoT) in urinalysis parameters, single parameters only to be listed if deviation from usual urine dip test.
E.g., leukocytes, nitrite, pH, protein, glucose, ketones, urobilinogen, bilirubin, blood/haemoglobin, measured in SI units.
Time frame: From baseline to EoT (Day 22)
Number of subjects with abnormal clinically significant findings of physical examination at Day 22 (EoT).
Evaluation of physical examination (areas skin, heart, lung, abdomen, basic neurological status, general examination of eyes, ears, nose, throat), overall evaluation, assessed by investigator as 'normal', 'abnormal not clinically significant', 'abnormal clinically significant'.
Time frame: EoT (Day 22)
Change from baseline to Day 22 (EoT) in systolic and diastolic blood pressure.
Measured in mmHg.
Time frame: From baseline to EoT (Day 22)
Change from baseline to Day 22 (EoT) in pulse.
Measured in beats per minute.
Time frame: From baseline to EoT (Day 22)
Frequency counts of overall tolerability assessment of skin reactions at Day 8, Day 15, Day 22, Day 36 and Day 50.
(Assessment performed by an investigator using a 4-point score \['0 = very good', '1 = good', '2 = moderate', '3 = poor'\]).
Time frame: From baseline up to trial end (Day 50)
Change from baseline (pre-dose at Day 1) to Day 22 (EoT) in psoriatic infiltrate thickness.
(Assessed by measurement of the thickness of the Echo Poor Band \[EPB\] of the inflammatory infiltrate using 22-MHz sonography; measured in µm).
Time frame: EoT (Day 22)
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2019 to primary completion in Oct 2019, 6 months.
Of 137 industry-sponsored phase 1 interventional studies under Psoriasis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 6 months is below that.
Counting every sponsor, half of 155 studies reached it within 10 months; a quarter within 5 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Calcipotriene